Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Theravance Biopharma, Inc.NASDAQ: TBPH

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin remains negative

Q1 FY2026 selling, general & admin was $17.72M, compared with $0 a year earlier. Trailing-twelve-month selling, general & admin was $37.58M. Over 3 fiscal years it compounded at +3.2% a year.

Context

  • Selling, general & admin amounted to 68.5% of revenue in FY2025, down 38.9 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $103.89M (+41.1%) for the fiscal year ending Dec 2026, a step up from the +6.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.72M-10.8% QoQ
Last fiscal yearDec 2025
$73.65M+6.5% YoY
LTMMar 2026
$37.58M+103.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+6.5%+41.1%+34.6 pp
3-year CAGR+3.2%+19.2%+16.0 pp
5-year CAGR+13.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
73.65M USD
Year-over-year change
+6.5%
4-year CAGR
-7.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +103.1% is the 2nd highest of 7, against a peer median of +15.0%.
  • Selling, general & admin amounts to 34.2% of revenue for TBPH, versus a peer median of 88.1%.
TBPH Competitors
Selling, General & Admin for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GERNGeron CorporationLTM Mar 2026$154.66M USD-2.5%+54.0%78.9%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$124.62M USD+263.0%+175.2%593.8%
VALNValneva SELTM Mar 2026€70.46M EUR-23.0%+9.1%45.1%
REPLReplimune Group, Inc.LTM Dec 2025$69.65M USD———
VIRVir Biotechnology, Inc.LTM Mar 2026$69.19M USD——105.6%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$37.85M USD+8.5%+10.0%88.1%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$37.58M USD+103.1%+3.2%34.2%
TYRATyra Biosciences, Inc.LTM Mar 2026$31.48M USD+21.6%+23.3%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$27.19M USD+59.1%+55.2%—
Peer median (excluding TBPH) —+15.0%+38.6%88.1%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.